Stockreport

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Corcept Therapeutics Incorporated  (CORT) 
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corcept.com/investors
PDF Hypercortisolism identified in 24 percent of patients with difficult-to-control type 2 diabetes REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporat [Read more]